Repatha FDA Approval History: Every Label Change From 2015 to Today

Original Approval: August 27, 2015

The FDA granted Repatha its initial approval on August 27, 2015, under BLA 125522, making evolocumab the first PCSK9 inhibitor to reach the U.S. market. The original label covered three patient populations: adults with HeFH, adults with HoFH, and adults with clinical ASCVD on maximally tolerated statin therapy who required additional LDL-C reduction.

Approval rested on the phase 3 PROFICIO program, which enrolled over 6,000 patients across multiple trials. In DESCARTES (N=901), evolocumab 420 mg monthly reduced LDL-C by 57% versus placebo at 52 weeks. The RUTHERFORD-2 trial showed a 59.2% LDL-C reduction in HeFH patients at 12 weeks. The FDA used an accelerated-style review pathway given the unmet need in statin-intolerant and refractory hypercholesterolemia. However, the agency explicitly noted that no cardiovascular-outcomes data existed at the time of approval. The label carried language stating that the effect of evolocumab on cardiovascular morbidity and mortality had "not been determined."

Amgen committed to completing a large outcomes trial (FOURIER) as a post-marketing requirement. That commitment shaped the next two years of Repatha's regulatory story.

The FOURIER Trial and Cardiovascular Outcomes Claim (2017)

FOURIER changed everything for Repatha's label. The FOURIER trial (N=27,564) randomized patients with established ASCVD and LDL-C ≥70 mg/dL (already on statin therapy) to evolocumab or placebo. At a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% (HR 0.85, 95% CI 0.79 to 0.92, P<0.001).

The key secondary endpoint (cardiovascular death, MI, or stroke) dropped by 20% (HR 0.80, 95% CI 0.73 to 0.88, P<0.001). Median LDL-C fell to 30 mg/dL in the evolocumab arm versus 92 mg/dL with placebo. These results, published in the New England Journal of Medicine in March 2017, gave the FDA what it needed to expand the label.

In December 2017, Amgen received approval of a supplemental BLA adding a cardiovascular risk-reduction indication. The updated label stated that Repatha is indicated "to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease." Dr. Marc Sabatine, the FOURIER principal investigator, stated: "The results demonstrated that the addition of evolocumab to statin therapy significantly reduced cardiovascular events, including heart attacks and strokes, in a broad population of patients with atherosclerotic disease."

This was a turning point for the entire PCSK9 inhibitor class. Payers who had restricted access pending outcomes data began loosening prior authorization criteria.

Pediatric Approvals and HoFH Label Updates

Repatha's approval path did not stop at adult cardiovascular disease. Amgen pursued pediatric indications in parallel, recognizing the severity of familial hypercholesterolemia in young patients.

For HeFH, the FDA approved Repatha for patients aged 10 years and older based on the HAUSER-RCT trial, which enrolled 157 pediatric patients (10 to 17 years). Evolocumab reduced LDL-C by 44.5% versus placebo at 24 weeks. The safety profile mirrored what was seen in adults: injection-site reactions occurred in 5.5% of patients.

For HoFH, the label originally covered adults only. Amgen later obtained a label update to include patients aged 13 years and older. The TAUSSIG study provided long-term open-label data in HoFH, showing sustained LDL-C reductions of approximately 20 to 30% over 4 years. Because HoFH patients often lack functional LDL receptors, the efficacy of all LDL-receptor-dependent therapies is attenuated in this population. PCSK9 inhibition works partly through upregulating LDL receptors, which means patients with receptor-negative HoFH respond less robustly.

The Endocrine Society 2020 clinical practice guideline now recommends considering PCSK9 inhibitors for pediatric FH patients who do not reach LDL-C targets on maximally tolerated statins and ezetimibe.

Manufacturing and Formulation History

Regulatory approvals involve more than clinical data. Amgen navigated several manufacturing and device-related supplements over the years.

Repatha launched in two delivery formats: a single-use prefilled SureClick autoinjector (140 mg/mL) and a single-use prefilled Pushtronex system (420 mg/3.5 mL on-body infusor for the monthly dose). The Pushtronex system allows patients to self-administer the 420 mg dose over approximately 5 minutes, avoiding three separate 140 mg injections.

Amgen also filed supplements related to manufacturing site changes and process improvements. These are tracked under the same BLA 125522 but do not alter the clinical label. Cold-chain requirements remain standard for monoclonal antibodies: Repatha must be stored refrigerated at 2 to 8°C, though it may be kept at room temperature (up to 25°C) for a maximum of 30 days in the original carton.

The FDA's Drugs@FDA database lists all approval actions, supplement history, and labeling revisions for BLA 125522.

Post-Market Safety Surveillance

The Repatha safety database now exceeds 40,000 patients from clinical trials, with additional real-world data from post-marketing surveillance and FDA Sentinel System analyses.

Early in the approval process, the FDA flagged neurocognitive events as a potential concern. Patients in some PCSK9 inhibitor trials reported memory complaints and confusion. To address this, the EBBINGHAUS study (a prespecified cognitive substudy of FOURIER, N=1,974) used the Cambridge Neuropsychological Test Automated Battery to evaluate executive function, working memory, and processing speed. Over a median follow-up of 19.4 months, evolocumab showed no signal for cognitive impairment compared to placebo, even among patients whose LDL-C dropped below 25 mg/dL.

Injection-site reactions remain the most common adverse event, reported in approximately 3 to 5% of patients. Nasopharyngitis (4.8%), upper respiratory tract infection (3.5%), and influenza (2.3%) appeared at rates comparable to placebo in FOURIER. Immunogenicity is low: binding antibodies developed in 0.3% of patients, and neutralizing antibodies were rare.

The current label does not carry a boxed warning. The FDA's post-marketing requirements (PMRs) for evolocumab included the completed FOURIER trial and ongoing pharmacovigilance for hypersensitivity and immunogenicity events.

Dr. Robert Eckel, former president of the American Heart Association, noted in a 2018 commentary: "The safety profile of PCSK9 inhibitors, including evolocumab, has proven remarkably clean across large-scale trials. Very low LDL-C concentrations do not appear to carry the neurological risks some clinicians feared."

How the Repatha Label Compares to Other PCSK9 Inhibitors

Repatha is not the only PCSK9 inhibitor with FDA approval. Praluent (alirocumab), manufactured by Sanofi/Regeneron, received FDA approval on July 24, 2015, roughly one month before Repatha. A third entrant, inclisiran (Leqvio), a small interfering RNA targeting PCSK9 synthesis, was approved on December 22, 2021.

Each carries distinct label language. The ODYSSEY Outcomes trial (N=18,924) supported alirocumab's cardiovascular-outcomes claim, with a 15% reduction in MACE (HR 0.85, 95% CI 0.78 to 0.93). Both Repatha and Praluent have nearly identical hazard ratios for their primary endpoints. Inclisiran's label, by contrast, is currently limited to LDL-C lowering and does not include a cardiovascular-outcomes indication. Its outcomes trial (ORION-4) has completed enrollment but full results are pending.

The dosing schedules differ considerably. Repatha is given every 2 weeks (140 mg) or monthly (420 mg). Praluent uses a biweekly 75 mg or 150 mg regimen. Inclisiran requires only twice-yearly injections after an initial loading period. These differences affect adherence, cost, and payer coverage decisions.

In terms of 2023 ACC/AHA guideline language, PCSK9 inhibitors are recommended as add-on therapy for very high-risk ASCVD patients whose LDL-C remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe. The guidelines do not preferentially recommend one PCSK9 inhibitor over another.

Pricing, Access, and Payer Coverage Timeline

Repatha's list price at launch in 2015 was approximately $14,100 per year. High cost became the defining barrier to uptake during the first three years. Payers imposed strict prior authorization requirements: patients typically needed documented statin intolerance, a failed trial of ezetimibe, and an LDL-C above a specific threshold.

Amgen reduced the list price by 60% in October 2018, bringing the annual wholesale acquisition cost to approximately $5,850. This move coincided with the availability of cardiovascular-outcomes data from FOURIER and growing payer acceptance. The Institute for Clinical and Economic Review (ICER) had previously estimated a value-based price range of $2,177 to $3,610 per year for PCSK9 inhibitors; the 2018 price reduction moved Repatha closer to that range.

Prescription volumes climbed following the price cut. Prior authorization denial rates dropped from over 70% in 2016 to under 30% by 2020 at many commercial payers. Medicare Part D coverage also expanded, particularly after CMS issued guidance reinforcing that PCSK9 inhibitors met the definition of medically accepted indications under the approved label.

The American College of Cardiology published a 2019 expert consensus decision pathway to help clinicians identify which patients should be considered for PCSK9 inhibitor therapy and how to manage the prior authorization process.

International Regulatory Actions

Outside the United States, Repatha has secured approval in more than 40 countries. The European Medicines Agency (EMA) approved evolocumab on July 17, 2015, slightly ahead of the FDA. The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended approval based on the same PROFICIO program data.

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved Repatha in January 2016. Health Canada followed in September 2015. Each regulatory body conducted independent reviews but reached consistent conclusions about the benefit-risk profile for LDL-C lowering in high-risk patients.

The EMA label was updated in 2018 to include the cardiovascular-outcomes indication based on FOURIER, tracking the FDA's December 2017 decision by approximately six months. Differences in label language are minor. The EMA specifies that treatment should be considered in the context of national guidelines, while the FDA label references specific LDL-C thresholds and patient populations.

What the Current Label Says

As of 2026, the Repatha label includes three distinct indications.

First, it is approved for adults with established ASCVD to reduce the risk of MI, stroke, and coronary revascularization. Second, it is indicated for adults and pediatric patients aged 10 years and older with HeFH as an adjunct to diet and maximally tolerated statin therapy. Third, it is approved for patients aged 13 years and older with HoFH as an adjunct to diet and other LDL-lowering therapies.

The label specifies two dosing regimens: 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously once monthly. Both achieve equivalent LDL-C lowering at steady state. The label also notes that evolocumab may be used with or without concomitant statin therapy, though the FOURIER benefit was demonstrated specifically in the statin-treated population.

Contraindications are limited to a history of serious hypersensitivity reaction to evolocumab. Lipid levels should be assessed 4 to 8 weeks after initiating therapy to guide dose adjustment and evaluate response.